Lo’ai Alanagreh

Risk of using hydroxychloroquine as a treatment of COVID-19

Lo’ai Alanagreh, Foad Alzoughool, Manar Atoum · International Journal of Risk & Safety in Medicine · 2020 · 37 citations · Full text

Heart Failure, Pharmacotherapy, Antimicrobial Chemotherapy +16

Coronavirus drugs: Using plasma from recovered patients as a treatment for COVID-19

Foad Alzoughool, Lo’ai Alanagreh · International Journal of Risk & Safety in Medicine · 2020 · 35 citations · Full text

Virus Epidemiology, Immunology, Pi Approach +19

Assessing intragenomic variation of the internal transcribed spacer two: Adapting the Illumina metagenomics protocol

Lo’ai Alanagreh, Caitlin Pegg, Amritha Harikumar et al. · PLoS ONE · 2017 · 26 citations · Full text

Engineering, Genetics, Genomics +20

Cerebrovascular comorbidity, high blood levels of C-reactive protein and D-dimer are associated with disease outcomes in COVID-19 patients

Foad Alzoughool, Lo’ai Alanagreh, Suhad Abumweis et al. · Clinical Hemorheology and Microcirculation · 2020 · 26 citations

Vascular Disease, Cerebrovascular Disease, Covid-19 Epidemiology +23

Irisin, leptin and adiponectin levels are reduced significantly during fasting

Foad Alzoughool, Huda Al Hourani, Manar Atoum et al. · Mediterranean Journal of Nutrition and Metabolism · 2019 · 12 citations